Pregabalin sustained-release - Jiangsu HengRui Medicine

Drug Profile

Pregabalin sustained-release - Jiangsu HengRui Medicine

Alternative Names: EASOPSRTFP; Pregabalin - Jiangsu HengRui Medicine

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Fibromyalgia; Postherpetic neuralgia

Most Recent Events

  • 01 May 2016 Phase-III clinical trials in Fibromyalgia in China (PO) (NCT02868814)
  • 28 Apr 2016 Jiangsu HengRui Medicine has an international patent protection for pregabalin sustained release
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top